Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 181 to 191 of 191 entries
Sorted by: Best Match Show Resources per page
Antithrombotic Therapy for Stroke Prevention in Patients With Ischemic Stroke With Aspirin Treatment Failure.

Stroke

Lusk JB, Xu H, Peterson ED, Bhatt DL, Fonarow GC, Smith EE, Matsouaka R, Schwamm LH, Xian Y.
PMID: 34702067
Stroke. 2021 Dec;52(12):e777-e781. doi: 10.1161/STROKEAHA.121.034622. Epub 2021 Oct 27.

BACKGROUND AND PURPOSE: Many older patients presenting with acute ischemic stroke were already taking aspirin before admission. However, the management strategy for patients with aspirin treatment failure has not been fully established.METHODS: We used data from the American Heart...

Cite
Lusk JB, Xu H, Peterson ED, et al. Antithrombotic Therapy for Stroke Prevention in Patients With Ischemic Stroke With Aspirin Treatment Failure. Stroke. 2021;52(12):e777-e781doi: 10.1161/STROKEAHA.121.034622.
Lusk, J. B., Xu, H., Peterson, E. D., Bhatt, D. L., Fonarow, G. C., Smith, E. E., Matsouaka, R., Schwamm, L. H., & Xian, Y. (2021). Antithrombotic Therapy for Stroke Prevention in Patients With Ischemic Stroke With Aspirin Treatment Failure. Stroke, 52(12), e777-e781. https://doi.org/10.1161/STROKEAHA.121.034622
Lusk, Jay B, et al. "Antithrombotic Therapy for Stroke Prevention in Patients With Ischemic Stroke With Aspirin Treatment Failure." Stroke vol. 52,12 (2021): e777-e781. doi: https://doi.org/10.1161/STROKEAHA.121.034622
Lusk JB, Xu H, Peterson ED, Bhatt DL, Fonarow GC, Smith EE, Matsouaka R, Schwamm LH, Xian Y. Antithrombotic Therapy for Stroke Prevention in Patients With Ischemic Stroke With Aspirin Treatment Failure. Stroke. 2021 Dec;52(12):e777-e781. doi: 10.1161/STROKEAHA.121.034622. Epub 2021 Oct 27. PMID: 34702067; PMCID: PMC8608737.
Copy Download .nbib Format: NLM
Non-Pharmaceutical Interventions and COVID-19 Burden in the United States.

medRxiv : the preprint server for health sciences

Ahlers MJ, Aralis HJ, Tang WL, Sussman JB, Fonarow GC, Ziaeian B.
PMID: 34611668
medRxiv. 2021 Sep 28; doi: 10.1101/2021.09.26.21264142.

BACKGROUND: Non-pharmaceutical interventions (NPIs) are mitigation strategies used to reduce the spread of transmissible diseases. The relative effectiveness of specific NPIs remains uncertain.METHODS: We used state-level Coronavirus disease 2019 (COVID-19) case and mortality data between January 19, 2020 and...

Cite
Ahlers MJ, Aralis HJ, Tang WL, et al. Non-Pharmaceutical Interventions and COVID-19 Burden in the United States. medRxiv. 2021;doi: 10.1101/2021.09.26.21264142.
Ahlers, M. J., Aralis, H. J., Tang, W. L., Sussman, J. B., Fonarow, G. C., & Ziaeian, B. (2021). Non-Pharmaceutical Interventions and COVID-19 Burden in the United States. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2021.09.26.21264142
Ahlers, Michael J, et al. "Non-Pharmaceutical Interventions and COVID-19 Burden in the United States." medRxiv : the preprint server for health sciences vol. (2021). doi: https://doi.org/10.1101/2021.09.26.21264142
Ahlers MJ, Aralis HJ, Tang WL, Sussman JB, Fonarow GC, Ziaeian B. Non-Pharmaceutical Interventions and COVID-19 Burden in the United States. medRxiv. 2021 Sep 28; doi: 10.1101/2021.09.26.21264142. PMID: 34611668; PMCID: PMC8491859.
Copy Download .nbib Format: NLM
Is the affordable care act medicaid expansion associated with receipt of heart failure guideline-directed medical therapy by race and ethnicity?.

American heart journal

Breathett KK, Xu H, Sweitzer NK, Calhoun E, Matsouaka RA, Yancy CW, Fonarow GC, DeVore AD, Bhatt DL, Peterson PN.
PMID: 34813771
Am Heart J. 2022 Feb;244:135-148. doi: 10.1016/j.ahj.2021.11.011. Epub 2021 Nov 20.

BACKGROUND: Uninsurance is a known contributor to racial/ethnic health inequities. Insurance is often needed for prescriptions and follow-up appointments. Therefore, we determined whether the Affordable Care Act(ACA) Medicaid Expansion was associated with increased receipt of guideline-directed medical treatment(GDMT) at...

Cite
Breathett KK, Xu H, Sweitzer NK, et al. Is the affordable care act medicaid expansion associated with receipt of heart failure guideline-directed medical therapy by race and ethnicity?. Am Heart J. 2021;244:135-148doi: 10.1016/j.ahj.2021.11.011.
Breathett, K. K., Xu, H., Sweitzer, N. K., Calhoun, E., Matsouaka, R. A., Yancy, C. W., Fonarow, G. C., DeVore, A. D., Bhatt, D. L., & Peterson, P. N. (2022). Is the affordable care act medicaid expansion associated with receipt of heart failure guideline-directed medical therapy by race and ethnicity?. American heart journal, 244135-148. https://doi.org/10.1016/j.ahj.2021.11.011
Breathett, Khadijah K, et al. "Is the affordable care act medicaid expansion associated with receipt of heart failure guideline-directed medical therapy by race and ethnicity?." American heart journal vol. 244 (2022): 135-148. doi: https://doi.org/10.1016/j.ahj.2021.11.011
Breathett KK, Xu H, Sweitzer NK, Calhoun E, Matsouaka RA, Yancy CW, Fonarow GC, DeVore AD, Bhatt DL, Peterson PN. Is the affordable care act medicaid expansion associated with receipt of heart failure guideline-directed medical therapy by race and ethnicity?. Am Heart J. 2022 Feb;244:135-148. doi: 10.1016/j.ahj.2021.11.011. Epub 2021 Nov 20. PMID: 34813771.
Copy Download .nbib Format: NLM
Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden.

European heart journal. Quality of care & clinical outcomes

Landmesser U, Lindgren P, Hagström E, van Hout B, Villa G, Pemberton-Ross P, Arellano J, Svensson ME, Sibartie M, Fonarow GC.
PMID: 33063111
Eur Heart J Qual Care Clin Outcomes. 2022 Jan 05;8(1):31-38. doi: 10.1093/ehjqcco/qcaa072.

AIMS: To assess the cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab added to standard-of-care lipid-lowering treatment [maximum tolerated dose (MTD) of statin and ezetimibe] in Swedish patients with a history of myocardial infarction (MI).METHODS AND RESULTS:...

Cite
Landmesser U, Lindgren P, Hagström E, et al. Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden. Eur Heart J Qual Care Clin Outcomes. 2022;8(1):31-38doi: 10.1093/ehjqcco/qcaa072.
Landmesser, U., Lindgren, P., Hagström, E., van Hout, B., Villa, G., Pemberton-Ross, P., Arellano, J., Svensson, M. E., Sibartie, M., & Fonarow, G. C. (2022). Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden. European heart journal. Quality of care & clinical outcomes, 8(1), 31-38. https://doi.org/10.1093/ehjqcco/qcaa072
Landmesser, Ulf, et al. "Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden." European heart journal. Quality of care & clinical outcomes vol. 8,1 (2022): 31-38. doi: https://doi.org/10.1093/ehjqcco/qcaa072
Landmesser U, Lindgren P, Hagström E, van Hout B, Villa G, Pemberton-Ross P, Arellano J, Svensson ME, Sibartie M, Fonarow GC. Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden. Eur Heart J Qual Care Clin Outcomes. 2022 Jan 05;8(1):31-38. doi: 10.1093/ehjqcco/qcaa072. PMID: 33063111.
Copy Download .nbib Format: NLM
Cost and Value in Contemporary Heart Failure Clinical Guidance Documents.

JACC. Heart failure

Ostrominski JW, Hirji S, Bhatt AS, Butler J, Fiuzat M, Fonarow GC, Heidenreich PA, Januzzi JL, Lam CSP, Maddox TM, O'Connor CM, Vaduganathan M.
PMID: 34969491
JACC Heart Fail. 2022 Jan;10(1):1-11. doi: 10.1016/j.jchf.2021.08.002. Epub 2021 Nov 10.

OBJECTIVES: This study sought to evaluate the frequency and nature of cost/value statements in contemporary heart failure (HF) clinical guidance documents (CGDs).BACKGROUND: In an era of rising health care costs and expanding therapeutic options, there is an increasing need...

Cite
Ostrominski JW, Hirji S, Bhatt AS, et al. Cost and Value in Contemporary Heart Failure Clinical Guidance Documents. JACC Heart Fail. 2021;10(1):1-11doi: 10.1016/j.jchf.2021.08.002.
Ostrominski, J. W., Hirji, S., Bhatt, A. S., Butler, J., Fiuzat, M., Fonarow, G. C., Heidenreich, P. A., Januzzi, J. L., Lam, C. S. P., Maddox, T. M., O'Connor, C. M., & Vaduganathan, M. (2022). Cost and Value in Contemporary Heart Failure Clinical Guidance Documents. JACC. Heart failure, 10(1), 1-11. https://doi.org/10.1016/j.jchf.2021.08.002
Ostrominski, John W, et al. "Cost and Value in Contemporary Heart Failure Clinical Guidance Documents." JACC. Heart failure vol. 10,1 (2022): 1-11. doi: https://doi.org/10.1016/j.jchf.2021.08.002
Ostrominski JW, Hirji S, Bhatt AS, Butler J, Fiuzat M, Fonarow GC, Heidenreich PA, Januzzi JL, Lam CSP, Maddox TM, O'Connor CM, Vaduganathan M. Cost and Value in Contemporary Heart Failure Clinical Guidance Documents. JACC Heart Fail. 2022 Jan;10(1):1-11. doi: 10.1016/j.jchf.2021.08.002. Epub 2021 Nov 10. PMID: 34969491.
Copy Download .nbib Format: NLM
Identifying Treatments for Stage C2 Heart Failure.

JAMA cardiology

Yancy CW, Hernandez AF, Fonarow GC.
PMID: 34643645
JAMA Cardiol. 2022 Jan 01;7(1):34-35. doi: 10.1001/jamacardio.2021.4024.

No abstract available.

Cite
Yancy CW, Hernandez AF, Fonarow GC. Identifying Treatments for Stage C2 Heart Failure. JAMA Cardiol. 2022;7(1):34-35doi: 10.1001/jamacardio.2021.4024.
Yancy, C. W., Hernandez, A. F., & Fonarow, G. C. (2022). Identifying Treatments for Stage C2 Heart Failure. JAMA cardiology, 7(1), 34-35. https://doi.org/10.1001/jamacardio.2021.4024
Yancy, Clyde W, et al. "Identifying Treatments for Stage C2 Heart Failure." JAMA cardiology vol. 7,1 (2022): 34-35. doi: https://doi.org/10.1001/jamacardio.2021.4024
Yancy CW, Hernandez AF, Fonarow GC. Identifying Treatments for Stage C2 Heart Failure. JAMA Cardiol. 2022 Jan 01;7(1):34-35. doi: 10.1001/jamacardio.2021.4024. PMID: 34643645.
Copy Download .nbib Format: NLM
Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry.

Circulation. Heart failure

Khan MS, Greene SJ, Hellkamp AS, DeVore AD, Shen X, Albert NM, Patterson JH, Spertus JA, Thomas LE, Williams FB, Hernandez AF, Fonarow GC, Butler J.
PMID: 34674536
Circ Heart Fail. 2021 Nov;14(11):e008351. doi: 10.1161/CIRCHEARTFAILURE.121.008351. Epub 2021 Oct 22.

BACKGROUND: Diuretics are a mainstay therapy for the symptomatic treatment of heart failure. However, in contemporary US outpatient practice, the degree to which diuretic dosing changes over time and the associations with clinical outcomes and health care resource utilization...

Cite
Khan MS, Greene SJ, Hellkamp AS, et al. Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry. Circ Heart Fail. 2021;14(11):e008351doi: 10.1161/CIRCHEARTFAILURE.121.008351.
Khan, M. S., Greene, S. J., Hellkamp, A. S., DeVore, A. D., Shen, X., Albert, N. M., Patterson, J. H., Spertus, J. A., Thomas, L. E., Williams, F. B., Hernandez, A. F., Fonarow, G. C., & Butler, J. (2021). Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry. Circulation. Heart failure, 14(11), e008351. https://doi.org/10.1161/CIRCHEARTFAILURE.121.008351
Khan, Muhammad Shahzeb, et al. "Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry." Circulation. Heart failure vol. 14,11 (2021): e008351. doi: https://doi.org/10.1161/CIRCHEARTFAILURE.121.008351
Khan MS, Greene SJ, Hellkamp AS, DeVore AD, Shen X, Albert NM, Patterson JH, Spertus JA, Thomas LE, Williams FB, Hernandez AF, Fonarow GC, Butler J. Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry. Circ Heart Fail. 2021 Nov;14(11):e008351. doi: 10.1161/CIRCHEARTFAILURE.121.008351. Epub 2021 Oct 22. PMID: 34674536.
Copy Download .nbib Format: NLM
Making heart failure count.

European journal of heart failure

Ziaeian B, Fonarow GC.
PMID: 33713517
Eur J Heart Fail. 2021 Jun;23(6):917-918. doi: 10.1002/ejhf.2148. Epub 2021 Mar 18.

No abstract available.

Cite
Ziaeian B, Fonarow GC. Making heart failure count. Eur J Heart Fail. 2021;23(6):917-918doi: 10.1002/ejhf.2148.
Ziaeian, B., & Fonarow, G. C. (2021). Making heart failure count. European journal of heart failure, 23(6), 917-918. https://doi.org/10.1002/ejhf.2148
Ziaeian, Boback, and Fonarow, Gregg C. "Making heart failure count." European journal of heart failure vol. 23,6 (2021): 917-918. doi: https://doi.org/10.1002/ejhf.2148
Ziaeian B, Fonarow GC. Making heart failure count. Eur J Heart Fail. 2021 Jun;23(6):917-918. doi: 10.1002/ejhf.2148. Epub 2021 Mar 18. PMID: 33713517; PMCID: PMC8286334.
Copy Download .nbib Format: NLM
Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors among Medicare Beneficiaries Hospitalized for Heart Failure.

Journal of cardiac failure

Vaduganathan M, Greene SJ, Zhang S, Solomon N, Chiswell K, DeVore AD, Butler J, Heidenreich PA, Huang JC, Kittleson MM, Maddox KEJ, McDermott JJ, Owens AT, Peterson PN, Solomon SD, Vardeny O, Yancy CW, Fonarow GC.
PMID: 34785402
J Card Fail. 2021 Nov 13; doi: 10.1016/j.cardfail.2021.11.010. Epub 2021 Nov 13.

BACKGROUND: The sodium-glucose cotransporter-2 (SGLT-2) inhibitors form the latest pillar in the management of heart failure with reduced ejection fraction (HFrEF) and appear effective across a range of patient profiles. There is increasing interest around initiation of SGLT-2 inhibitor...

Cite
Vaduganathan M, Greene SJ, Zhang S, et al. Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors among Medicare Beneficiaries Hospitalized for Heart Failure. J Card Fail. 2021;doi: 10.1016/j.cardfail.2021.11.010.
Vaduganathan, M., Greene, S. J., Zhang, S., Solomon, N., Chiswell, K., DeVore, A. D., Butler, J., Heidenreich, P. A., Huang, J. C., Kittleson, M. M., Maddox, K. E. J., McDermott, J. J., Owens, A. T., Peterson, P. N., Solomon, S. D., Vardeny, O., Yancy, C. W., & Fonarow, G. C. (2021). Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors among Medicare Beneficiaries Hospitalized for Heart Failure. Journal of cardiac failure, . https://doi.org/10.1016/j.cardfail.2021.11.010
Vaduganathan, Muthiah, et al. "Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors among Medicare Beneficiaries Hospitalized for Heart Failure." Journal of cardiac failure vol. (2021). doi: https://doi.org/10.1016/j.cardfail.2021.11.010
Vaduganathan M, Greene SJ, Zhang S, Solomon N, Chiswell K, DeVore AD, Butler J, Heidenreich PA, Huang JC, Kittleson MM, Maddox KEJ, McDermott JJ, Owens AT, Peterson PN, Solomon SD, Vardeny O, Yancy CW, Fonarow GC. Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors among Medicare Beneficiaries Hospitalized for Heart Failure. J Card Fail. 2021 Nov 13; doi: 10.1016/j.cardfail.2021.11.010. Epub 2021 Nov 13. PMID: 34785402.
Copy Download .nbib Format: NLM
A Brief Overview of Recurrent Pericarditis Management and the Potential of Rilonacept as a New Therapeutic Option.

American journal of cardiovascular drugs : drugs, devices, and other interventions

Gupta M, Kaul S, Velazquez GR, Bandyopadhyay D, Fonarow GC, Klein A, Ghosh RK.
PMID: 34008144
Am J Cardiovasc Drugs. 2022 Jan;22(1):27-33. doi: 10.1007/s40256-021-00481-x. Epub 2021 May 19.

Recurrent pericarditis affects 15-30% of patients after acute pericarditis. A large number of the patients with recurrent pericarditis can become corticosteroid dependent, leading to disease chronicity and drug dependence, with additional morbidity from long-term steroid use. Recent randomized trials...

Cite
Gupta M, Kaul S, Velazquez GR, et al. A Brief Overview of Recurrent Pericarditis Management and the Potential of Rilonacept as a New Therapeutic Option. Am J Cardiovasc Drugs. 2021;22(1):27-33doi: 10.1007/s40256-021-00481-x.
Gupta, M., Kaul, S., Velazquez, G. R., Bandyopadhyay, D., Fonarow, G. C., Klein, A., & Ghosh, R. K. (2022). A Brief Overview of Recurrent Pericarditis Management and the Potential of Rilonacept as a New Therapeutic Option. American journal of cardiovascular drugs : drugs, devices, and other interventions, 22(1), 27-33. https://doi.org/10.1007/s40256-021-00481-x
Gupta, Manasvi, et al. "A Brief Overview of Recurrent Pericarditis Management and the Potential of Rilonacept as a New Therapeutic Option." American journal of cardiovascular drugs : drugs, devices, and other interventions vol. 22,1 (2022): 27-33. doi: https://doi.org/10.1007/s40256-021-00481-x
Gupta M, Kaul S, Velazquez GR, Bandyopadhyay D, Fonarow GC, Klein A, Ghosh RK. A Brief Overview of Recurrent Pericarditis Management and the Potential of Rilonacept as a New Therapeutic Option. Am J Cardiovasc Drugs. 2022 Jan;22(1):27-33. doi: 10.1007/s40256-021-00481-x. Epub 2021 May 19. PMID: 34008144.
Copy Download .nbib Format: NLM
Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US.

JAMA cardiology

Vaduganathan M, Claggett BL, Greene SJ, Aggarwal R, Bhatt AS, McMurray JJV, Fonarow GC, Solomon SD.
PMID: 34524394
JAMA Cardiol. 2021 Sep 15; doi: 10.1001/jamacardio.2021.3651. Epub 2021 Sep 15.

IMPORTANCE: The US Food and Drug Administration (FDA) expanded labeling for sacubitril/valsartan for use in individuals with chronic heart failure (HF) with left ventricular ejection fraction (LVEF) lower than normal. The population-level implications of implementation of sacubitril/valsartan at higher...

Cite
Vaduganathan M, Claggett BL, Greene SJ, et al. Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US. JAMA Cardiol. 2021;doi: 10.1001/jamacardio.2021.3651.
Vaduganathan, M., Claggett, B. L., Greene, S. J., Aggarwal, R., Bhatt, A. S., McMurray, J. J. V., Fonarow, G. C., & Solomon, S. D. (2021). Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US. JAMA cardiology, . https://doi.org/10.1001/jamacardio.2021.3651
Vaduganathan, Muthiah, et al. "Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US." JAMA cardiology vol. (2021). doi: https://doi.org/10.1001/jamacardio.2021.3651
Vaduganathan M, Claggett BL, Greene SJ, Aggarwal R, Bhatt AS, McMurray JJV, Fonarow GC, Solomon SD. Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US. JAMA Cardiol. 2021 Sep 15; doi: 10.1001/jamacardio.2021.3651. Epub 2021 Sep 15. PMID: 34524394; PMCID: PMC8444065.
Copy Download .nbib Format: NLM
Showing 181 to 191 of 191 entries